---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-003949"
form_type: "8-K"
ticker: "VCYT"
cik: "0001384101"
company_name: "VERACYTE, INC."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:07:28.881964+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Veracyte acquires C2i Genomics for $70M in stock; reports preliminary 2023 revenue up 21%

## Summary
- Q4 2023 revenue $95-96M (+18-20% YoY); full-year revenue $358-359M (+21%).
- Total test volume ~34,000 in Q4 (+21%), ~127,000 full-year (+24%).
- 2024 revenue guidance 10-12% growth ($394-402M); cash >$215M at year-end.
- Acquires C2i Genomics for $70M in Veracyte shares at close plus up to $25M milestone; expected close Q1 2024.
- First MRD test in muscle-invasive bladder cancer, leveraging urology commercial channel.

## SEC filing metadata
- accession: 0001193125-24-003949
- form_type: 8-K
- ticker: VCYT
- cik: 0001384101
- company_name: VERACYTE, INC.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1384101/000119312524003949/0001193125-24-003949-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1384101/000119312524003949/d543036d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-003949
- JSON: https://secwatch.observer/filing/0001193125-24-003949.json
- Plain text: https://secwatch.observer/filing/0001193125-24-003949.txt

## Key facts
- Earnings Releases
  VERACYTE, INC. reported the full year ended December 31, 2023 results: revenue between $358.0 million and $359.0 million.
  - Period: the full year ended December 31, 2023
  - Revenue: between $358.0 million and $359.0 million
  - Result: preliminary results
  source text: For the full year ended December 31, 2023, as compared to the same period of 2022, Veracyte expects to report: • Revenue of between $358 million and $359 million, an increase of 21%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1384101/000119312524003949/0001193125-24-003949-index.htm
- Earnings Releases
  VERACYTE, INC. reported the fourth quarter ended December 31, 2023 results: revenue between $95.0 million and $96.0 million.
  - Period: the fourth quarter ended December 31, 2023
  - Revenue: between $95.0 million and $96.0 million
  - Result: preliminary results
  source text: For the fourth quarter ended December 31, 2023, as compared to the same period of 2022, Veracyte expects to report: • Revenue of between $95 million and $96 million, an increase of between 18% and 20%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1384101/000119312524003949/0001193125-24-003949-index.htm
- Earnings Releases
  VERACYTE, INC. reported full year 2024 results: revenue between $394 million and $402 million. Guidance initiated.
  - Period: full year 2024
  - Revenue: between $394 million and $402 million
  - Guidance: initiated
  - Result: guidance update
  source text: Veracyte is initiating 2024 testing and product revenue guidance of 13% to 15% growth, partially offset by declining biopharma and other revenue, resulting in total company revenue growth of 10% to 12%, or $394 million to $402 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1384101/000119312524003949/0001193125-24-003949-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.